Publication details
Závažné erythema exsudativum multiforme jako projev kožní toxicity po kombinované imunoterapii
| Title in English | Severe erythema exsudativum multiforme as a manifestation of skin toxicity after combination immunotherapy |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Referátový výběr z dermatovenerologie |
| MU Faculty or unit | |
| Citation | |
| Web | http://referatovyvyber.cz/dermatovenerologie/images/flippingbook/RVD-2-2023/rvd-2-2023.pdf |
| Keywords | immune-relatedadverse event |
| Description | Immunotherapy as a modern method of cancer treatment brings, besides many benefits, also a risk adverse events (ir-AEs). These result from a specific mechanism of action that interferes with the regulation of the immune system. In most cases, these adverse effects of immunotherapy are reversible. In particular, during the induction phase of treatment, there may be the development of a cutaneous toxic reaction (grade I-IV). A crucial step in the management of skin toxicity is early initiation of immunosuppressive treatment with corticosteroids after exclusion of infectious etiology of exanthema. After consideration of the risk/benefit ratio, immunotherapy can be continued after the skin problems have healed. It is important to be aware of this knowledge of this issue by first-line physicians, an interdisciplinary approach and patient education. The following case report presents the case of a patient with the development of severe erythema exsudativum multiforme after administration of the first cycle of combination immunotherapy (nivolumab + ipilimumab) in the treatment of disseminated renal tumor. |